224 related articles for article (PubMed ID: 32139270)
21. Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer.
Choi JE; Kang SH; Lee SJ; Bae YK
Ann Surg Oncol; 2015 Jan; 22(1):82-9. PubMed ID: 25145503
[TBL] [Abstract][Full Text] [Related]
22. Prognostic significance of androgen receptor expression in HER2-positive and triple-negative breast cancer.
Kucukzeybek BB; Bayoglu IV; Kucukzeybek Y; Yıldız Y; Oflazoglu U; Atahan MK; Taskaynatan H; Alacacioglu A; Yigit S; Tarhan MO
Pol J Pathol; 2018; 69(2):157-168. PubMed ID: 30351863
[TBL] [Abstract][Full Text] [Related]
23. Clinical and pathological factors influencing survival in a large cohort of triple-negative breast cancer patients.
Urru SAM; Gallus S; Bosetti C; Moi T; Medda R; Sollai E; Murgia A; Sanges F; Pira G; Manca A; Palmas D; Floris M; Asunis AM; Atzori F; Carru C; D'Incalci M; Ghiani M; Marras V; Onnis D; Santona MC; Sarobba G; Valle E; Canu L; Cossu S; Bulfone A; Rocca PC; De Miglio MR; Orrù S
BMC Cancer; 2018 Jan; 18(1):56. PubMed ID: 29310602
[TBL] [Abstract][Full Text] [Related]
24.
Uzelac B; Krivokuca A; Susnjar S; Milovanovic Z; Supic G
Genet Test Mol Biomarkers; 2021 Mar; 25(3):227-235. PubMed ID: 33734898
[No Abstract] [Full Text] [Related]
25. Prognostic value of long non-coding RNAs in triple negative breast cancer: A PRISMA-compliant meta-analysis.
Zhang S; Ma F; Xie X; Shen Y
Medicine (Baltimore); 2020 Sep; 99(37):e21861. PubMed ID: 32925722
[TBL] [Abstract][Full Text] [Related]
26. Tumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor-positive breast cancers.
Krishnamurti U; Wetherilt CS; Yang J; Peng L; Li X
Hum Pathol; 2017 Jun; 64():7-12. PubMed ID: 28153508
[TBL] [Abstract][Full Text] [Related]
27. Androgen Receptor mRNA levels determine the prognosis in triple-negative breast cancer patients.
Govindan S; Siraganahalli Eswaraiah M; Basavaraj C; Adinarayan M; Sankaran S; Bakre M
BMC Cancer; 2020 Aug; 20(1):745. PubMed ID: 32778063
[TBL] [Abstract][Full Text] [Related]
28. Identification of tRNA-derived small noncoding RNAs as potential biomarkers for prediction of recurrence in triple-negative breast cancer.
Feng W; Li Y; Chu J; Li J; Zhang Y; Ding X; Fu Z; Li W; Huang X; Yin Y
Cancer Med; 2018 Oct; 7(10):5130-5144. PubMed ID: 30239174
[TBL] [Abstract][Full Text] [Related]
29. Androgen receptor positive triple negative breast cancer: Clinicopathologic, prognostic, and predictive features.
Astvatsaturyan K; Yue Y; Walts AE; Bose S
PLoS One; 2018; 13(6):e0197827. PubMed ID: 29883487
[TBL] [Abstract][Full Text] [Related]
30. The Prognostic Role of Androgen Receptor in Patients with Early-Stage Breast Cancer: A Meta-analysis of Clinical and Gene Expression Data.
Bozovic-Spasojevic I; Zardavas D; Brohée S; Ameye L; Fumagalli D; Ades F; de Azambuja E; Bareche Y; Piccart M; Paesmans M; Sotiriou C
Clin Cancer Res; 2017 Jun; 23(11):2702-2712. PubMed ID: 28151718
[No Abstract] [Full Text] [Related]
31. Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: a systematic review and meta-analysis.
Gao G; Wang Z; Qu X; Zhang Z
BMC Cancer; 2020 Mar; 20(1):179. PubMed ID: 32131780
[TBL] [Abstract][Full Text] [Related]
32. Identification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast cancer.
Yu KD; Zhu R; Zhan M; Rodriguez AA; Yang W; Wong S; Makris A; Lehmann BD; Chen X; Mayer I; Pietenpol JA; Shao ZM; Symmans WF; Chang JC
Clin Cancer Res; 2013 May; 19(10):2723-33. PubMed ID: 23549873
[TBL] [Abstract][Full Text] [Related]
33. Breast-conserving therapy for triple-negative breast cancer.
Gangi A; Chung A; Mirocha J; Liou DZ; Leong T; Giuliano AE
JAMA Surg; 2014 Mar; 149(3):252-8. PubMed ID: 24382582
[TBL] [Abstract][Full Text] [Related]
34. Integration of whole-genome sequencing and functional screening identifies a prognostic signature for lung metastasis in triple-negative breast cancer.
Xie G; Yang H; Ma D; Sun Y; Chen H; Hu X; Jiang YZ; Shao ZM
Int J Cancer; 2019 Nov; 145(10):2850-2860. PubMed ID: 30977117
[TBL] [Abstract][Full Text] [Related]
35. Androgen receptor expression predicts beneficial tamoxifen response in oestrogen receptor-α-negative breast cancer.
Hilborn E; Gacic J; Fornander T; Nordenskjöld B; Stål O; Jansson A
Br J Cancer; 2016 Feb; 114(3):248-55. PubMed ID: 26742006
[TBL] [Abstract][Full Text] [Related]
36. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N
Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308
[TBL] [Abstract][Full Text] [Related]
37. Biological and clinical significance of flap endonuclease‑1 in triple‑negative breast cancer: Support of metastasis and a poor prognosis.
Xu L; Qu JL; Song N; Zhang LY; Zeng X; Che XF; Hou KZ; Shi S; Feng ZY; Qu XJ; Liu YP; Teng YE
Oncol Rep; 2020 Dec; 44(6):2443-2454. PubMed ID: 33125141
[TBL] [Abstract][Full Text] [Related]
38. MiRNAs Predict the Prognosis of Patients with Triple Negative Breast Cancer: A Meta-Analysis.
Liu Y; Zhang Y; Li Q; Li J; Ma X; Xing J; Rong S; Wu Z; Tian Y; Li J; Jia L
PLoS One; 2017; 12(1):e0170088. PubMed ID: 28085956
[TBL] [Abstract][Full Text] [Related]
39. Prognostic role of PIK3CA mutations of cell-free DNA in early-stage triple negative breast cancer.
Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Inao T; Sueta A; Fujiwara S; Omoto Y; Iwase H
Cancer Sci; 2015 Nov; 106(11):1582-9. PubMed ID: 26353837
[TBL] [Abstract][Full Text] [Related]
40. Analysis of Risk of Recurrence by Subtype in ≤ 1-cm Breast Tumors.
Colonna SV; Higgins AK; Alvarez J; Saville BR; Lawrence J; Abramson VG
Clin Breast Cancer; 2016 Jun; 16(3):223-31. PubMed ID: 26683741
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
